Abstract
Glycosylation, linking the glycan chains to protein or lipid, is the most common and complex post-translational modifications of proteins. One of the important functions of glycoprotein is to maintain the ordered social life of each cell in multicellular organisms. Glycosylation is sensitive to the biochemical environment leading to the alteration of glycan chains under the physiological condition and specific diseases such as cancer. Cancer and other lethal diseases cannot be diagnosed at early stage due to classic biomarker’s low sensitivity and specificity. Recently, the development of glycan profiling technologies has offered great promises for understanding the complex glycan structures and has increased interest in applying this technology for cancer studies. In this regard, to identify the glycans as the potential biomarkers of cancer has become an important direction for clinical cancer diagnosis. This paper summarizes the current research on validating and developing of the glycans as new cancer biomarkers and the nascent field of glycomics
Keywords: Cancer biomarker, glycomics, N-glycan, oligosaccharide, personalized medicine, public health pharmacogenomics.
Current Pharmacogenomics and Personalized Medicine
Title:Validation and Development of N-glycan as Biomarker in Cancer Diagnosis
Volume: 11 Issue: 1
Author(s): Wei Wang
Affiliation:
Keywords: Cancer biomarker, glycomics, N-glycan, oligosaccharide, personalized medicine, public health pharmacogenomics.
Abstract: Glycosylation, linking the glycan chains to protein or lipid, is the most common and complex post-translational modifications of proteins. One of the important functions of glycoprotein is to maintain the ordered social life of each cell in multicellular organisms. Glycosylation is sensitive to the biochemical environment leading to the alteration of glycan chains under the physiological condition and specific diseases such as cancer. Cancer and other lethal diseases cannot be diagnosed at early stage due to classic biomarker’s low sensitivity and specificity. Recently, the development of glycan profiling technologies has offered great promises for understanding the complex glycan structures and has increased interest in applying this technology for cancer studies. In this regard, to identify the glycans as the potential biomarkers of cancer has become an important direction for clinical cancer diagnosis. This paper summarizes the current research on validating and developing of the glycans as new cancer biomarkers and the nascent field of glycomics
Export Options
About this article
Cite this article as:
Wang Wei, Validation and Development of N-glycan as Biomarker in Cancer Diagnosis, Current Pharmacogenomics and Personalized Medicine 2013; 11 (1) . https://dx.doi.org/10.2174/1875692111311010008
DOI https://dx.doi.org/10.2174/1875692111311010008 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the Treatment of Glioblastoma Multiforme
Current Medicinal Chemistry Recent Advances in Cancer Therapy: An Overview
Current Pharmaceutical Design Vasoactive Factors and Diabetic Retinopathy: Vascular Endothelial Growth Factor, Cycoloxygenase-2 and Nitric Oxide
Current Pharmaceutical Design An Expanding Appreciation of the Role Chemokine Receptors Play in Cancer Progression
Current Pharmaceutical Design Antimetastatic Activities and Mechanisms of Bisdioxopiperazine Compounds
Anti-Cancer Agents in Medicinal Chemistry Mechanisms of Cytotoxicity of Anticancer Titanocenes
Anti-Cancer Agents in Medicinal Chemistry Important Aspects of Post-Prandial Antidiabetic Drug, Acarbose
Current Topics in Medicinal Chemistry Animal Models for the Evaluation of Theranostic Radiopharmaceuticals
Current Radiopharmaceuticals FoxO1 Inhibitors: The Future Medicine for Metabolic Disorders?
Current Diabetes Reviews Green Tea Catechins as Novel Antitumor and Antiangiogenic Compounds
Current Medicinal Chemistry - Anti-Cancer Agents Naturally Occurring NF-κB Inhibitors
Mini-Reviews in Medicinal Chemistry Rational Combination of Targeted Therapies As A Strategy to Overcome The Mechanisms of Resistance to Inhibitors of EGFR Signaling
Current Pharmaceutical Design The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment
Current Pharmaceutical Design Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology Significant Metabolites and Outlier-Robust Classifier Identification for Breast Cancer Prediction
Current Metabolomics PLCO: Evolution of an Epidemiologic Resource and Opportunities for Future Studies
Reviews on Recent Clinical Trials Cancer Stem Cells of Head and Neck Squamous Cell Carcinoma
Current Cancer Therapy Reviews Inhibition of Hyaluronan Synthase-3 Decreases Subcutaneous Colon Cancer Growth by Increasing Apoptosis
Anti-Cancer Agents in Medicinal Chemistry The Relation Between Stereochemistry and Biological Activity of Platinum(II) Complexes Chelated with Chiral Diamine Ligands: An Intricate Problem
Current Pharmaceutical Design Metabolic Enzyme System and Transport Pathways in Chronic Kidney Diseases
Current Drug Metabolism